EDO platform demonstrates potentially best-in-class safety and efficacy profile in addressing DMD and DM1 disease phenotypes Advancing rapidly to the clinic with first-in-human studies expected to initiate in early 2022 […]
Pratteln, Switzerland, March 3, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that the last patient has completed the last visit for the first period of the placebo-controlled pivotal VISION-DMD study with […]
************** Join CureDuchenne and Sarepta on March 4 for a webinar discussing the below announcement. CureDuchenne Webinar: Sarepta Therapeutics update on RNA Exon-Skipping program and Patient Support Services In this […]
Dear Duchenne Community, All of us at Italfarmaco would like to thank the families participating in the Phase 3 EPIDYS trial and in the open label extension study of givinostat […]
PTC Therapeutics shared the below letter to the Duchenne community. We are pleased to see the results of the dystrophin study (Study 045) and thankful for PTC’s longtime commitment to […]
CureDuchenne is pleased to share news that Avidity Biosciences has announced exciting details of its Duchenne program today, the full press release is below. CureDuchenne Ventures made an investment in […]
— Study met the primary biological endpoint of micro-dystrophin protein expression at 12 weeks post-treatment, as measured by western blot, in SRP-9001-treated participants versus placebo — — SRP-9001-treated participants showed […]
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 CIFFREO study, which will evaluate the efficacy and safety of investigational […]
– Pivotal program for RGX-314, potential best-in-class, one-time gene therapy for the treatment of wet AMD, is active and expected to support BLA filing in 2024— Recently completed an End […]
